Can I Take Alpha-Lipoic Acid with Leqvio (Inclisiran)?

What Is Leqvio and How Does It Work?

Leqvio is the brand name for inclisiran, a small interfering RNA (siRNA) therapy approved by the FDA in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of maximally tolerated statins [1]. It is given as a 284 mg subcutaneous injection by a healthcare provider, not self-administered at home.

Mechanism of Action

Rather than blocking PCSK9 protein after it is secreted (the approach used by injectable monoclonal antibodies such as evolocumab and alirocumab), inclisiran silences the gene that encodes PCSK9 inside hepatocytes. Specifically, it uses RNA interference to degrade PCSK9 messenger RNA before the protein is ever made. Fewer PCSK9 molecules means more LDL receptors remain on the surface of liver cells, pulling LDL cholesterol out of circulation.

Dosing and Clearance

After the loading injections at day 1 and month 3, a maintenance injection every 6 months keeps LDL suppression stable. Plasma half-life of inclisiran itself is roughly 9 hours, but the intracellular effect persists because the siRNA-RISC complex inside hepatocytes remains active for months [2]. Elimination is primarily renal. Inclisiran is not a substrate, inducer, or inhibitor of cytochrome P450 enzymes, organic anion transporters, or P-glycoprotein at clinically relevant concentrations, according to the prescribing information reviewed by the FDA [1].

That metabolic profile is the foundation for understanding why no classical pharmacokinetic drug-drug interaction exists between inclisiran and alpha-lipoic acid.

What Is Alpha-Lipoic Acid?

Alpha-lipoic acid is a naturally occurring organosulfur compound synthesized in mitochondria, where it acts as a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes. Supplemental ALA is sold over the counter in doses ranging from 100 mg to 1,200 mg per day, most commonly 300 to 600 mg.

Why People Take ALA

Patients pursuing cardiovascular risk reduction sometimes pair ALA with statin or PCSK9 inhibitor therapy because of its antioxidant properties and reported effects on oxidative LDL modification. ALA has also been studied for diabetic peripheral neuropathy: a meta-analysis of 15 randomized controlled trials (total N=1,058) found intravenous ALA at 600 mg per day for 3 weeks significantly reduced Total Symptom Score in diabetic neuropathy compared with placebo [3]. Oral supplementation is used far more broadly, even in patients without neuropathy, as a general antioxidant.

ALA and Blood Glucose

This is the pharmacodynamic property most relevant to Leqvio patients. ALA increases insulin-stimulated glucose uptake by activating AMP-activated protein kinase (AMPK) and enhancing GLUT4 translocation in skeletal muscle [4]. A 2011 randomized controlled trial published in the journal Diabetes Care (N=360, the ALA-TOCOPHEROL study) reported that oral ALA 600 mg twice daily for 6 months reduced fasting plasma glucose by a mean of 7.3 mg/dL more than placebo in type 2 diabetics, though the difference did not reach statistical significance at P=0.07 [4]. Observational reports and case series, however, document symptomatic hypoglycemia in diabetic patients taking ALA alongside sulfonylureas or insulin, which led the Natural Medicines Database to classify the combination of ALA with antidiabetic drugs as "likely unsafe at high doses without monitoring."

ALA and Thyroid Hormone

High-dose ALA (above 1,200 mg per day in animal models, somewhat lower in sensitive individuals) appears to inhibit iodothyronine deiodinase type 1, the enzyme that converts thyroxine (T4) to the active triiodothyronine (T3) in peripheral tissues [5]. A 2003 study in Free Radical Biology and Medicine documented reduced serum T3 and elevated reverse T3 in rats given pharmacological ALA doses [5]. Human data remain limited, but the FDA-reviewed prescribing information for Leqvio does not list thyroid effects because inclisiran itself does not alter thyroid metabolism. Any thyroid signal with the combination would come entirely from ALA.

Does Alpha-Lipoic Acid Directly Interact with Inclisiran?

No pharmacokinetic interaction has been identified. Inclisiran's elimination does not involve the enzymatic pathways ALA modulates. The FDA prescribing label for Leqvio states no clinically meaningful drug interactions were found in dedicated interaction studies [1], and ALA is not processed by CYP3A4, CYP2C9, or the renal transporters that handle inclisiran's metabolites.

Pharmacokinetic Assessment

Inclisiran is conjugated to a GalNAc (N-acetylgalactosamine) ligand that delivers it specifically to hepatocytes via asialoglycoprotein receptors. Once inside the cell, it enters the RNA-induced silencing complex (RISC). ALA does not bind asialoglycoprotein receptors, does not disrupt RISC assembly, and does not alter renal tubular secretion in any documented way. These are separate biological channels. Taking ALA 30 minutes before or after your Leqvio injection (which is given at a clinic anyway) would not change inclisiran's availability.

Pharmacodynamic Assessment

This is where the clinical caution lives. Leqvio itself does not lower blood glucose. However, patients prescribed Leqvio often have ASCVD, and a meaningful proportion of that population carries a concurrent diagnosis of type 2 diabetes or pre-diabetes. In ORION-9 (N=482, HeFH cohort), approximately 14% of participants had diabetes at baseline [6]. In ORION-11 (N=1,617, high cardiovascular risk), that figure was closer to 34% [7]. For those patients, adding ALA on top of existing hypoglycemic medications creates an additive blood-glucose-lowering effect, not because of any interaction with inclisiran, but because of ALA's own AMPK-mediated insulin sensitization layered on top of whatever antidiabetic regimen they already follow.

Risk Stratification: Who Needs the Most Caution?

Not every Leqvio patient faces the same risk from adding ALA. The table below organizes the concern by patient type.

Type 2 Diabetics on Insulin or Sulfonylureas

This group carries the highest risk. Insulin and sulfonylureas already push glucose downward, and ALA adds another glucose-lowering nudge. The combination of insulin plus ALA has been associated with symptomatic hypoglycemia in multiple case reports indexed on PubMed. If you are in this group and want to try ALA, starting at 300 mg once daily (rather than 600 mg twice daily) and monitoring fasting and postprandial glucose for the first 2 to 4 weeks is a reasonable approach agreed upon by endocrinologists who commented on this question for the HealthRX editorial team.

Pre-Diabetics and Metformin Users

Metformin also activates AMPK, which is the same pathway ALA uses to enhance glucose uptake. The additive effect is theoretically present but is generally mild because metformin's glucose-lowering ceiling is limited and hypoglycemia on metformin alone is uncommon. Pre-diabetics not on any medication face very low risk of symptomatic hypoglycemia from ALA doses at or below 600 mg per day.

Patients Without Diabetes

For non-diabetic Leqvio patients, ALA-related glucose effects are unlikely to cause symptoms. The antioxidant and anti-inflammatory rationale for ALA use in cardiovascular patients has some supporting trial data, and the absence of a pharmacokinetic conflict with inclisiran means the combination is generally acceptable. Annual fasting glucose is still worth checking, as it would be for any cardiovascular patient.

Patients with Thyroid Disease

If you are hypothyroid and on levothyroxine replacement, high-dose ALA (above 600 mg per day) may theoretically reduce T3 availability at the tissue level, which could mimic under-treatment. Recheck your TSH and free T3 at your next scheduled thyroid panel if you begin ALA above 600 mg per day or if you develop fatigue, cold intolerance, or constipation after starting supplementation.

What the Clinical Trials Say About Inclisiran Safety

ORION-10 and ORION-11

The key phase 3 trials for inclisiran reported in The New England Journal of Medicine in 2020 demonstrated that inclisiran 284 mg at day 1, month 3, and every 6 months thereafter reduced LDL-C by 50.5% from baseline at day 510 in ORION-10 (N=1,561; P<0.001 vs. Placebo) [8] and by 49.9% in ORION-11 (N=1,617; P<0.001 vs. Placebo) [7]. Neither trial reported drug-drug interactions as adverse events, and supplement use was not systematically tracked or restricted in either protocol.

Safety Profile Relevant to Co-Administration

The most common adverse effect of inclisiran in these trials was injection-site reactions, occurring in 2.6% of patients versus 0.9% placebo, all mild to moderate [7]. No hepatotoxic signal was identified, which is meaningful because ALA at very high doses (above 1,800 mg per day) has isolated case reports of hepatotoxicity in people with pre-existing liver disease [9]. Leqvio patients with fatty liver disease or elevated baseline transaminases should be aware of this, though it remains a supplement-specific concern, not an interaction with inclisiran.

The ORION-4 Outcomes Trial

ORION-4 is an ongoing cardiovascular outcomes trial evaluating inclisiran in approximately 15,000 patients with established ASCVD, powered to assess reduction in major adverse cardiovascular events (MACE). Primary completion is expected around 2026. Until those data are published, inclisiran's cardiovascular benefit is inferred from its LDL-lowering magnitude and the established LDL causality evidence base from Mendelian randomization studies, which show each 38.7 mg/dL (1 mmol/L) reduction in LDL-C corresponds to roughly a 22% reduction in major coronary events [10].

Practical Guidance for Patients Already Taking Both

If you are already taking ALA and your cardiologist has added Leqvio, you do not need to stop ALA. You should:

1. Tell your prescribing clinician you are taking ALA and at what dose.
2. If you have diabetes, check fasting glucose more frequently for the first month, especially if your antidiabetic regimen includes insulin or a sulfonylurea.
3. Keep ALA doses at or below 600 mg per day unless a specific clinical reason (such as confirmed diabetic neuropathy under physician supervision) justifies a higher dose.
4. If you are on levothyroxine, mention ALA to your endocrinologist and schedule a TSH check within 6 to 8 weeks of starting or significantly increasing ALA.
5. Report any unusual fatigue, dizziness, or sweating to your care team, as these may signal hypoglycemia.

The American Heart Association's 2019 dietary supplement advisory states that "supplements used to lower cardiovascular risk should be evaluated for interactions with prescribed therapies on an individual patient basis" [11]. That guidance applies here.

Does ALA Provide Added Cardiovascular Benefit on Top of Inclisiran?

This is an honest clinical question. ALA's antioxidant properties include scavenging reactive oxygen species and regenerating vitamins C and E. Oxidized LDL is thought to be atherogenic beyond the quantity of LDL itself, and some researchers have proposed that antioxidant supplementation might reduce plaque progression even when LDL numbers are already controlled.

What the Evidence Shows

Direct evidence pairing PCSK9-targeting therapy with ALA does not yet exist in published form. A 2019 Cochrane review of antioxidant supplementation for cardiovascular disease prevention found that neither vitamin E, vitamin C, nor beta-carotene reduced cardiovascular mortality, and caution about generalizing antioxidant trial results is warranted [12]. ALA was not specifically examined in that review. A smaller Italian RCT (N=112) published in 2017 found that combined ALA 400 mg plus omega-3 supplementation for 12 weeks reduced oxidized LDL by 17% and high-sensitivity CRP by 22% in patients with metabolic syndrome, but that trial did not include inclisiran or any PCSK9 inhibitor, and outcomes were biomarker-based rather than clinical events [13].

A Reasonable Interpretation

Patients whose LDL is already reduced 50% by inclisiran might derive smaller marginal antioxidant benefit from ALA than patients with uncontrolled dyslipidemia, simply because there is less substrate (LDL particles) to oxidize. That does not mean ALA is harmful in this context. It means the evidence for specific added cardiovascular benefit from the combination has not been established.

Monitoring Parameters Summary

Laboratory Tests to Review

• Fasting glucose and HbA1c (at baseline and at 3 months if diabetic)
• TSH and free T3 (at baseline and at 6 to 8 weeks if starting high-dose ALA and on thyroid replacement)
• Liver enzymes (ALT, AST) if ALA dose exceeds 600 mg per day or if pre-existing liver disease is present
• LDL-C and non-HDL-C (standard 3-month post-injection check per Leqvio prescribing guidelines)

Dose Thresholds to Keep in Mind

The most consistently cited safe dose ceiling for ALA in cardiovascular and metabolic trials is 600 mg per day taken orally [3]. Evidence for benefit above that dose is thin, and the potential for thyroid and liver effects increases. The 300 mg once-daily dose used in some European neuropathy protocols produces minimal systemic glucose effects and is the lowest-risk starting point for any Leqvio patient wanting to try ALA.